Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Oct;81(10):e204.
doi: 10.1136/annrheumdis-2020-218710. Epub 2020 Sep 9.

Tocilizumab for the treatment of polyarteritis nodosa: a systematic literature review. Correspondence on 'Tofacitinib for polyarteritis nodosa: a tailored therapy' by Rimar et al

Mitsuhiro Akiyama  1 , Yuko Kaneko  2 , Tsutomu Takeuchi  1
Affiliations
Free article
Comment

Tocilizumab for the treatment of polyarteritis nodosa: a systematic literature review. Correspondence on 'Tofacitinib for polyarteritis nodosa: a tailored therapy' by Rimar et al

Mitsuhiro Akiyama et al. Ann Rheum Dis. 2022 Oct.
Free article
No abstract available

Keywords: autoimmune diseases; biological therapy; cardiovascular diseases; cytokines.

PubMed Disclaimer

Conflict of interest statement

Competing interests: MA reports no conflicts of interest relevant to this article. YK has received grants or speaker fees from AbbVie, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Hisamitsu, Jansen, Kissei, Pfizer, Sanofi, Takeda, Tanabe-Mitsubishi and UCB. TT has received research grants or speaking fees from Astellas Pharma Inc, Bristol–Myers KK, Chugai Pharmaceutical Co, Ltd, Daiichi Sankyo Co, Ltd, Takeda Pharmaceutical Co, Ltd, Teijin Pharma Ltd, AbbVie GK, Asahi Kasei Pharma Corp, Mitsubishi Tanabe Pharma, Astra Zeneca KK, Eli Lilly Japan KK, Novartis Pharma KK, AbbVie GK, Nippon Kayaku Co Ltd, Janssen Pharmaceutical KK, Taiho Pharmaceutical Co, Ltd and Pfizer Japan Inc.

Comment in

Comment on

  • Tofacitinib for polyarteritis nodosa: a tailored therapy.
    Rimar D, Alpert A, Starosvetsky E, Rosner I, Slobodin G, Rozenbaum M, Kaly L, Boulman N, Awisat A, Ginsberg S, Zilber K, Shen-Orr SS. Rimar D, et al. Ann Rheum Dis. 2016 Dec;75(12):2214-2216. doi: 10.1136/annrheumdis-2016-209330. Epub 2016 Aug 24. Ann Rheum Dis. 2016. PMID: 27558986 No abstract available.

LinkOut - more resources